Literature DB >> 6819143

Decreased serum carnitine in valproate induced Reye syndrome.

H Böhles, K Richter, E Wagner-Thiessen, H Schäfer.   

Abstract

A 3-year-old girl developed acute liver disease after treatment with valproate for 6 months. She developed the typical features of Reye syndrome. Serum free carnitine was decreased as well as 3-keto-valproic acid, the main metabolite of beta-oxidation of valproate. The serum valproate concentration was at the upper limit of the therapeutic range. The possible importance of carnitine in the pathogenesis of valproate induced liver disease is discussed.

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 6819143     DOI： 10.1007/bf01377353

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN： 0340-6199            Impact factor:   3.183


  14 in total

1.  ENZYMOLOGICAL DETERMINATION OF FREE CARNITINE CONCENTRATIONS IN RAT TISSUES.

Authors:  N R MARQUIS; I B FRITZ
Journal:  J Lipid Res       Date:  1964-04       Impact factor: 5.922

2.  Reye-like syndrome associated with valproic acid therapy.

Authors:  N Gerber; R G Dickinson; R C Harland; R K Lynn; L D Houghton; J I Antonias; J C Schimschock
Journal:  J Pediatr       Date:  1979-07       Impact factor: 4.406

3.  Acute hepatic failure associated with the use of sodium valproate.

Authors:  F J Suchy; W F Balistreri; J J Buchino; J M Sondheimer; S R Bates; G L Kearns; J D Stull; K E Bove
Journal:  N Engl J Med       Date:  1979-04-26       Impact factor: 91.245

4.  On the mechanism of inhibition of fatty acid oxidation by 4-pentenoic acid in rat liver mitochondria.

Authors:  M H Fukami; J R Williamson
Journal:  J Biol Chem       Date:  1971-03-10       Impact factor: 5.157

5.  Fatal hepatic failure and sodium valproate.

Authors:  G Le Bihan; J Bourreille; M Sampson; J Leroy; A M Szekely; A Coquerel
Journal:  Lancet       Date:  1980-12-13       Impact factor: 79.321

6.  Fatal Reye-like syndrome associated with valproic acid.

Authors:  R S Young; I Bergman; D L Gang; E P Richardson
Journal:  Ann Neurol       Date:  1980-04       Impact factor: 10.422

7.  Systemic carnitine deficiency simulating recurrent Reye syndrome.

Authors:  A M Glasgow; G Eng; A G Engel
Journal:  J Pediatr       Date:  1980-05       Impact factor: 4.406

8.  Amino acid pattern in Reye syndrome: comparison with clinically similar entities.

Authors:  C A Romshe; M D Hilty; H J McClung; B Kerzner; C B Reiner
Journal:  J Pediatr       Date:  1981-05       Impact factor: 4.406

9.  Production of the features of Reye's syndrome in rats with 4-pentenoic acid.

Authors:  A M Glasgow; H P Chase
Journal:  Pediatr Res       Date:  1975-03       Impact factor: 3.756

10.  Systemic carnitine deficiency--a treatable inherited lipid-storage disease presenting as Reye's syndrome.

Authors:  P R Chapoy; C Angelini; W J Brown; J E Stiff; A L Shug; S D Cederbaum
Journal:  N Engl J Med       Date:  1980-12-11       Impact factor: 91.245
View more
  12 in total

Review 1.  Delineating the role of alterations in lipid metabolism to the pathogenesis of inherited skeletal and cardiac muscle disorders: Thematic Review Series: Genetics of Human Lipid Diseases.

Authors:  Harjot K Saini-Chohan; Ryan W Mitchell; Frédéric M Vaz; Teresa Zelinski; Grant M Hatch
Journal:  J Lipid Res       Date:  2011-11-07       Impact factor: 5.922

Review 2.  Biochemical relationships between Reye's and Reye's-like metabolic and toxicological syndromes.

Authors:  J Osterloh; W Cunningham; A Dixon; D Combest
Journal:  Med Toxicol Adverse Drug Exp       Date:  1989 Jul-Aug

3.  Heterozygotes for plasmalemmal carnitine transporter defect are at increased risk for valproic acid-associated impairment of carnitine uptake in cultured human skin fibroblasts.

Authors:  I Tein; S DiMauro; Z W Xie; D C De Vivo
Journal:  J Inherit Metab Dis       Date:  1995       Impact factor: 4.982

4.  Carnitine metabolism and inborn errors.

Authors:  A G Engel; C J Rebouche
Journal:  J Inherit Metab Dis       Date:  1984       Impact factor: 4.982

Review 5.  Carnitine transport: pathophysiology and metabolism of known molecular defects.

Authors:  I Tein
Journal:  J Inherit Metab Dis       Date:  2003       Impact factor: 4.982

Review 6.  Valproate-associated hepatotoxicity and its biochemical mechanisms.

Authors:  M J Eadie; W D Hooper; R G Dickinson
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Mar-Apr

7.  Short-term effects of administration of anticonvulsant drugs on free carnitine and acylcarnitine in mouse serum and tissues.

Authors:  M F Camiña; I Rozas; M Gómez; J M Paz; C Alonso; S Rodriguez-Segade
Journal:  Br J Pharmacol       Date:  1991-05       Impact factor: 8.739

Review 8.  Valproate hepatotoxicity syndrome: hypotheses of pathogenesis.

Authors:  J R Stephens; R H Levy
Journal:  Pharm Weekbl Sci       Date:  1992-06-19

9.  Plasma and hepatic carnitine and coenzyme A pools in a patient with fatal, valproate induced hepatotoxicity.

Authors:  S Krähenbühl; G Mang; H Kupferschmidt; P J Meier; M Krause
Journal:  Gut       Date:  1995-07       Impact factor: 23.059

10.  Carnitine plasma concentrations in 353 metabolically healthy children.

Authors:  E Schmidt-Sommerfeld; D Werner; D Penn
Journal:  Eur J Pediatr       Date:  1988-05       Impact factor: 3.183
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.